Patents Examined by Marianne DiBrino
-
Patent number: 12115214Abstract: The invention relates a compound comprising (a) a peptide and (b) a carrier, wherein said peptide having at least the motif X-X-X-X-X-X-X, wherein at least one amino acid residue X is glycosylated, said peptide being linked to the peptide binding protein and said carrier comprises at least a MHC binding motif being linked to said peptide as well as pharmaceutical compositions comprising said compound and the use of said compound or pharmaceutical composition for the treatment of a disease, such as an inflammatory joint disease. The subject matter of the application is exemplified with peptides derived from type II collagen such as peptides having at least the sequence AGFKGEA, or IAGFKGEQPKG, or the peptide AAAKAAA. Preferably a hydroxylysine in the peptides are glycosylated.Type: GrantFiled: November 15, 2019Date of Patent: October 15, 2024Assignee: Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V.Inventors: Rikard Holmdahl, Jan Kihlberg, Balik Dzhambazov, Mikael Vestberg
-
Patent number: 12084478Abstract: Fusion peptide inhibitors of human coronavirus 229E are provided. The fusion peptide inhibitors of HCOV-229E include peptide #121 (SEQ?ID?NO:?2:?HVLGDISGINASVVQIQKEIDRLNEVAKNLHESL IYLQE),?and?peptide? #125?(SEQ?ID?NO:?3:?HRLRQIRGIRARVVQIQKEIWRLNEVAKL LNESLIYLQE). The fusion peptide inhibitors of HCoV-229E may be administered to a subject in need thereof to inhibit or prevent HCOV-229E cellular entry or infection with HCoV-229E. The fusion peptide inhibitors of HCoV-229E may also be used in HCoV-229E inhibition assays.Type: GrantFiled: September 25, 2023Date of Patent: September 10, 2024Assignee: KING FAISAL UNIVERSITYInventor: Mahmoud Kandeel
-
Patent number: 12053512Abstract: The invention provides a method of validating the therapeutic composition that is prepared for immunotherapy of a tumor or cancer. The method includes, triggering of an immune response to a neoepitope of a subject's tumor by: a) obtaining neoepitope sequence data from the tumor of a subject; b) obtaining immune competent cells; c) using the neoepitope sequence data to generate a neoepitope presentation system; d) triggering an immune response by contacting the immune competent cells with the neoepitope presentation system; and e) quantifying the triggering of the immune response from the contacted immune competent cells.Type: GrantFiled: December 5, 2017Date of Patent: August 6, 2024Assignees: NantBio, Inc., Nant Holdings IP, LLC, NantOmics, LLCInventors: Kayvan Niazi, Nicholas J. Witchey, Stephen Charles Benz, Shahrooz Rabizadeh
-
Patent number: 12044680Abstract: The methods and kits disclosed in the present disclosure allow quantified exchange of peptides into MHC proteins. These methods and kits allow MHC proteins with exchanged peptides to be used in further applications such as cell staining. The methods and kits may also be used to quantify peptides present in complex mixtures.Type: GrantFiled: May 12, 2017Date of Patent: July 23, 2024Assignee: MBL International Corp.Inventor: Marc Delcommenne
-
Patent number: 12011480Abstract: This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of TR1 cells and/or B cells in an antigen-specific manner and treating diseases and disorders in a subject in need thereof.Type: GrantFiled: May 6, 2016Date of Patent: June 18, 2024Assignee: UTI LIMITED PARTNERSHIPInventor: Pedro Santamaria
-
Patent number: 11992504Abstract: A recombinant natural killer (NK) cell or T-cell composition is transfected with a nucleic acid encoding i) a homing receptor; ii) an antigen binding protein (ABP) or a chimeric antigen receptor (CAR) that specifically binds a target antigen; iii) an Fc Receptor; and/or iv) a secreted immune modulator selected from a TGF? inhibitor and/or IL-12, where the recombinant cell is gamma (?)-irradiated conferring inhibition of cell proliferation with transient activity of the transfected molecules including the secreted immune modulators for up to 72 hours.Type: GrantFiled: November 20, 2020Date of Patent: May 28, 2024Assignee: ImmunityBio, Inc.Inventors: John H. Lee, Laurent H. Boissel, Hans G. Klingemann
-
Patent number: 11987606Abstract: The disclosure features compounds comprising an antigen portion, a soluble Major Histocompatibility Complex (MHC) molecule portion (e.g., all or an antigen-binding portion of a soluble MHC class I molecule), and a dynamic anchor portion (e.g., an agent, such as Annexin V, that binds to phosphatidylserine). The featured compounds are useful for a variety of therapeutic applications, including, e.g., enhancing a T cell response to an antigen of interest or enhancing a T cell-driven immune response by a subject to an antigen of interest (e.g., a cancer antigen or a microbial antigen).Type: GrantFiled: March 4, 2016Date of Patent: May 21, 2024Assignee: The Johns Hopkins UniversityInventors: Tzyy-Choou Wu, Chih-Ping Mao, Chien-Fu Hung
-
Patent number: 11988669Abstract: The present invention relates to a method for the absolute quantification of naturally processed HLA-restricted cancer peptides, i.e. the determination of the copy number of peptide(s) as presented per cell. The present invention can not only be used for the development of antibody therapies or peptide vaccines, but is also highly valuable for a molecularly defined immuno-monitoring, and useful in the processes of identifying of new peptide antigens for immunotherapeutic strategies, such as respective vaccines, antibody-based therapies or adoptive T-cell transfer approaches in cancer, infectious and/or autoimmune diseases.Type: GrantFiled: November 15, 2019Date of Patent: May 21, 2024Assignee: Immatics Biotechnologies GmbHInventors: Toni Weinschenk, Julia Leibold
-
Patent number: 11957729Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: July 12, 2019Date of Patent: April 16, 2024Assignee: Immatics Biotechnologies GmbHInventors: Hans Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas, Toni Weinschenk, Peter Lewandrowski
-
Patent number: 11952431Abstract: Disclosed are peptides that specifically bind to neutrophils and uses thereof for neutrophil-targeted delivery of drugs or diagnostic agents in medical conditions including cancer as well as infectious, inflammatory and autoimmune diseases or disorders.Type: GrantFiled: December 27, 2022Date of Patent: April 9, 2024Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEIDCAL RESEARCH SERVICES & DEVELOPMENT LTD.Inventors: Zvika Granot, Zvi Gregorio Fridlender, Sandra Vols
-
Patent number: 11939354Abstract: Fusion peptide inhibitors of human coronavirus 229E are provided. The fusion peptide inhibitors of HCoV-229E include peptide #121 (SEQ ID NO: 2: HVLGDISGINASVVQIQKEIDRLNEVAKNLHESLIYLQE), and peptide #125 (SEQ ID NO: 3: HRLRQIRGIRARVVQIQKEIWRLNEVAKLLNESLIYLQE). The fusion peptide inhibitors of HCoV-229E may be administered to a subject in need thereof to inhibit or prevent HCoV-229E cellular entry or infection with HCoV-229E. The fusion peptide inhibitors of HCoV-229E may also be used in HCoV-229E inhibition assays.Type: GrantFiled: September 25, 2023Date of Patent: March 26, 2024Assignee: KING FAISAL UNIVERSITYInventor: Mahmoud Kandeel
-
Patent number: 11939595Abstract: This disclosure provides nano-scale Artificial Antigen Presenting Cells (aAPC), which deliver stimulatory signals to lymphocytes, including T-helper lymphocytes, for use as a powerful tool for immunotherapy.Type: GrantFiled: August 23, 2019Date of Patent: March 26, 2024Assignee: The Johns Hopkins UniversityInventors: Jonathan Schneck, Mathias Oelke, Karlo Perica
-
Patent number: 11904053Abstract: The present technology relates generally to dry powder formulations of antibodies specific for thymic stromal lymphopoietin (TSLP), as well as methods of treating asthma, using the dry powder formulations, suitably via pulmonary delivery.Type: GrantFiled: October 27, 2020Date of Patent: February 20, 2024Assignee: MEDIMMUNE LIMITEDInventors: Catherine Eugenie Chaillan Huntington, Susan Hoe, Prakash Manikwar, Roland Wilhelm Kolbeck, Emma Suzanne Cohen, David Lechuga-Ballesteros, Kellisa Beth Hansen, Dexter Joseph D'Sa, Saba Ghazvini
-
Patent number: 11866461Abstract: Fusion peptide inhibitors of human coronavirus 229E are provided. The fusion peptide inhibitors of HCoV-229E include peptide #121 (SEQ ID NO: 2: HVLGDISGINASVVQIQKEIDRLNEVAKNLHESLIYLQE), and peptide #125 (SEQ ID NO: 3: HRLRQIRGIRARVVQIQKEIWRLNEVAKLLNESLIYLQE). The fusion peptide inhibitors of HCoV-229E may be administered to a subject in need thereof to inhibit or prevent HCoV-229E cellular entry or infection with HCoV-229E. The fusion peptide inhibitors of HCoV-229E may also be used in HCoV-229E inhibition assays.Type: GrantFiled: May 16, 2023Date of Patent: January 9, 2024Assignee: KING FAISAL UNIVERSITYInventor: Mahmoud Kandeel
-
Patent number: 11859176Abstract: A method for in vitro activation and/or expansion of immune cells is provided, including the steps of: a) providing magnetic particles having multi-protrusive surface modified with at least one type of immuno-inducing substance, in which each magnetic particle includes a copolymer core, a polymer layer, a magnetic substance layer, and a silicon-based layer from the inside to the outside; b) providing a cell solution including at least one type of immune cell in the cell solution; and c) bringing the magnetic particles in contact with the cell solution, in which the at least one type of immuno-inducing substance on the surface of the magnetic particle activates and/or expands the at least one type of immune cell in the cell solution.Type: GrantFiled: December 21, 2018Date of Patent: January 2, 2024Assignees: Industrial Technology Research Institute, National Taiwan University HospitalInventors: Cheng-Tai Chen, Chien-An Chen, Wen-Ting Chiang, Su-Feng Chiu, Pei-Shin Jiang, Jih-Luh Tang, Chien-Ting Lin, Xuan-Hui Lin
-
Patent number: 11833220Abstract: Provided are an artificial multi-antigen fusion protein and a preparation method thereof. The fusion protein can effectively stimulate CD8+T and CD4+ T cell immunities, and can be applied to immunodiagnostics or serve as a prophylactic or therapeutic vaccine.Type: GrantFiled: December 15, 2015Date of Patent: December 5, 2023Assignees: Oxford Vacmedix UK Ltd.Inventors: Shisong Jiang, Xiaobing Xia, Hanghai Ding
-
Patent number: 11819516Abstract: Provided herein is technology relating to immunotherapy and particularly, but not exclusively, to compositions, methods, and kits for immunotherapy and activation of T cells using a peptide-major histocompatibility complex (pMHC) assembled on a protein scaffold for patterned signal presentation of T cell activating ligands to T cells.Type: GrantFiled: November 4, 2016Date of Patent: November 21, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Fei Wen, Mason Smith
-
Patent number: 11813318Abstract: The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a beta-2 microglobulin (B2M) gene, which results in deficiency in MHC class I expression and function. Also provided are the method of using the cells for transplantation and treating a disease condition.Type: GrantFiled: July 10, 2019Date of Patent: November 14, 2023Assignee: UNIVERSITY OF WASHINGTONInventors: David W. Russell, Roli K. Hirata
-
Patent number: 11807675Abstract: The present invention relates to, in part, artificial antigen presenting cells that are useful in treating disease (including cancers) and have uses, for example, directly in vivo and/or in the expansion of a patients cells for re-introduction ex vivo.Type: GrantFiled: October 3, 2014Date of Patent: November 7, 2023Assignee: The University of Maryland, BaltimoreInventors: Tonya Webb, Carolyn Morris, James East
-
Patent number: 11787849Abstract: The invention describes kit of parts of polypeptides comprising: a) a peptide comprising: a1) an MHC class II T cell epitope or a CD1 d-restricted NKT cell epitope, and a2) immediately adjacent to said epitope or separated by at most 7 amino acids from said epitope a [CST]-X(2)-C [SEQ ID NO:7] or C-X(2)-[CST] [SEQ ID NO:8] oxidoreductase motif sequence, and b) a polypeptide comprising: b1) a therapeutic protein and b2) the epitope defined in a1), wherein the epitope sequence is a sequence which differs from the sequence of the protein of b1). The therapeutic protein, in combination with the peptide, is used to prevent an immune response against the therapeutic protein.Type: GrantFiled: September 23, 2016Date of Patent: October 17, 2023Assignee: IMCYSE SAInventors: Jean-Marie Saint-Remy, Luc Vander Elst, Vincent Carlier